Exact Mass: 826.3574

Exact Mass Matches: 826.3574

Found 42 metabolites which its exact mass value is equals to given mass value 826.3574, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Atractyloside F

Atractyloside F

C37H62O20 (826.3834)


   

PGP(i-12:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R))

[(2S)-3-({[(2R)-2-{[(5R,6Z,8E,10E,12S,14Z)-5,12-dihydroxyicosa-6,8,10,14-tetraenoyl]oxy}-3-[(10-methylundecanoyl)oxy]propoxy](hydroxy)phosphoryl}oxy)-2-hydroxypropoxy]phosphonic acid

C38H68O15P2 (826.4033)


PGP(i-12:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R)) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(i-12:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R)), in particular, consists of one chain of one 10-methylundecanoyl at the C-1 position and one chain of Leukotriene B4 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

   

PGP(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/i-12:0)

[(2S)-3-({[(2R)-3-{[(5S,6Z,8E,10E,12R,14Z)-5,12-dihydroxyicosa-6,8,10,14-tetraenoyl]oxy}-2-[(10-methylundecanoyl)oxy]propoxy](hydroxy)phosphoryl}oxy)-2-hydroxypropoxy]phosphonic acid

C38H68O15P2 (826.4033)


PGP(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/i-12:0) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/i-12:0), in particular, consists of one chain of one Leukotriene B4 at the C-1 position and one chain of 10-methylundecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

   

PGP(i-12:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S))

[(2S)-3-({[(2R)-2-{[(5S,6E,8Z,11Z,13E,15R)-5,15-dihydroxyicosa-6,8,11,13-tetraenoyl]oxy}-3-[(10-methylundecanoyl)oxy]propoxy](hydroxy)phosphoryl}oxy)-2-hydroxypropoxy]phosphonic acid

C38H68O15P2 (826.4033)


PGP(i-12:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S)) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(i-12:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S)), in particular, consists of one chain of one 10-methylundecanoyl at the C-1 position and one chain of 5(S),15(S)-Dihydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

   

PGP(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/i-12:0)

[(2S)-3-({[(2R)-3-{[(5R,6E,8Z,11Z,13E,15S)-5,15-dihydroxyicosa-6,8,11,13-tetraenoyl]oxy}-2-[(10-methylundecanoyl)oxy]propoxy](hydroxy)phosphoryl}oxy)-2-hydroxypropoxy]phosphonic acid

C38H68O15P2 (826.4033)


PGP(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/i-12:0) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/i-12:0), in particular, consists of one chain of one 5(S),15(S)-Dihydroxyeicosatetraenoyl at the C-1 position and one chain of 10-methylundecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

   

PGP(i-12:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R))

[(2S)-3-({[(2R)-2-{[(5R,6R,8Z,11Z,14Z,17Z)-5,6-dihydroxyicosa-8,11,14,17-tetraenoyl]oxy}-3-[(10-methylundecanoyl)oxy]propoxy](hydroxy)phosphoryl}oxy)-2-hydroxypropoxy]phosphonic acid

C38H68O15P2 (826.4033)


PGP(i-12:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(i-12:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)), in particular, consists of one chain of one 10-methylundecanoyl at the C-1 position and one chain of 5,6-Dihydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

   

PGP(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/i-12:0)

[(2S)-3-({[(2R)-3-{[(5S,6S,8Z,11Z,14Z,17Z)-5,6-dihydroxyicosa-8,11,14,17-tetraenoyl]oxy}-2-[(10-methylundecanoyl)oxy]propoxy](hydroxy)phosphoryl}oxy)-2-hydroxypropoxy]phosphonic acid

C38H68O15P2 (826.4033)


PGP(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/i-12:0) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/i-12:0), in particular, consists of one chain of one 5,6-Dihydroxyeicosatetraenoyl at the C-1 position and one chain of 10-methylundecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

   

5-[(2S,3S)-3-[[2-(2-hydroxy-5-prop-2-enylphenyl)-4-prop-2-enylphenoxy]methyl]-7-prop-2-enyl-5-(4-prop-2-enylphenoxy)-2,3-dihydro-1,4-benzodioxin-2-yl]-3-(4-prop-2-enylphenoxy)benzene-1,2-diol

5-[(2S,3S)-3-[[2-(2-hydroxy-5-prop-2-enylphenyl)-4-prop-2-enylphenoxy]methyl]-7-prop-2-enyl-5-(4-prop-2-enylphenoxy)-2,3-dihydro-1,4-benzodioxin-2-yl]-3-(4-prop-2-enylphenoxy)benzene-1,2-diol

C54H50O8 (826.3506)


   

cyclo(Leu-Trp-Pro3-Phe-Gly-Pro6-Glu)|hymenamide C|iso-hymenamide C

cyclo(Leu-Trp-Pro3-Phe-Gly-Pro6-Glu)|hymenamide C|iso-hymenamide C

C43H54N8O9 (826.4014)


   

Oleandrigenin-3beta-O-(beta-D-digitoxosido-4-beta-D-xylosido-3beta-D-apiosid)|Oleandrigenin-3beta-O-

Oleandrigenin-3beta-O-(beta-D-digitoxosido-4-beta-D-xylosido-3beta-D-apiosid)|Oleandrigenin-3beta-O-

C41H62O17 (826.3987)


   

3beta-O-[beta-D-galactopyranosyl-(1?2)-beta-D-glucopyranosiduronic acid]-3-hydroxy-30-norlanost-8(9)-ene-28,29-dioic acid|uraboside B

3beta-O-[beta-D-galactopyranosyl-(1?2)-beta-D-glucopyranosiduronic acid]-3-hydroxy-30-norlanost-8(9)-ene-28,29-dioic acid|uraboside B

C41H62O17 (826.3987)


   

2,23-disulfate ester of niga-ichigoside F1|3,23-disulfate ester of 2alpha,3beta,19alpha,23-tetrahydroxyurs-12-en-28-oic acid 28-O-beta-D-glucopyranoside

2,23-disulfate ester of niga-ichigoside F1|3,23-disulfate ester of 2alpha,3beta,19alpha,23-tetrahydroxyurs-12-en-28-oic acid 28-O-beta-D-glucopyranoside

C36H58O17S2 (826.3115)


   

1,6-Ditrityl-Surose,,

1,6-Ditrityl-Surose,,

C50H50O11 (826.3353)


   
   
   

[2-butyl-3-[[4-[2-[1-[[2-butyl-5-chloro-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methyl]tetrazol-5-yl]phenyl]phenyl]methyl]-5-chloroimidazol-4-yl]methanol

[2-butyl-3-[[4-[2-[1-[[2-butyl-5-chloro-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methyl]tetrazol-5-yl]phenyl]phenyl]methyl]-5-chloroimidazol-4-yl]methanol

C44H44Cl2N12O (826.3138)


   

[2-butyl-1-[2-[2-[[2-butyl-4-chloro-1-[[2-(1H-tetrazol-5-yl) biphenyl-4-yl]methyl]-1H-imidazol-5-yl]methyl]-2H-tetrazol-5-yl]biphenyl-4-yl]methyl-4-chloro-1H-imidazol-5-yl]methanol

[2-butyl-1-[2-[2-[[2-butyl-4-chloro-1-[[2-(1H-tetrazol-5-yl) biphenyl-4-yl]methyl]-1H-imidazol-5-yl]methyl]-2H-tetrazol-5-yl]biphenyl-4-yl]methyl-4-chloro-1H-imidazol-5-yl]methanol

C44H44Cl2N12O (826.3138)


   

PGP(i-12:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R))

PGP(i-12:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R))

C38H68O15P2 (826.4033)


   

PGP(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/i-12:0)

PGP(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/i-12:0)

C38H68O15P2 (826.4033)


   

PGP(i-12:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S))

PGP(i-12:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S))

C38H68O15P2 (826.4033)


   

PGP(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/i-12:0)

PGP(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/i-12:0)

C38H68O15P2 (826.4033)


   

PGP(i-12:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R))

PGP(i-12:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R))

C38H68O15P2 (826.4033)


   

PGP(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/i-12:0)

PGP(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/i-12:0)

C38H68O15P2 (826.4033)


   

cyclo[Glu-DL-Leu-DL-Trp-DL-Pro-DL-Phe-Gly-DL-Pro]

3-[(21S)-6-benzyl-15-(1H-indol-3-ylmethyl)-18-(2-methylpropyl)-2,5,8,14,17,20,23-heptaoxo-1,4,7,13,16,19,22-heptazatricyclo[22.3.0.09,13]heptacosan-21-yl]propanoic acid

C43H54N8O9 (826.4014)


   
   

PI 20:5/12:3;O2

PI 20:5/12:3;O2

C41H63O15P (826.3904)


   
   

atractyloside f

NA

C37H62O20 (826.3834)


{"Ingredient_id": "HBIN017306","Ingredient_name": "atractyloside f","Alias": "NA","Ingredient_formula": "C37H62O20","Ingredient_Smile": "CC12CCC(CC1C(=C)CC(C2)OC3C(C(C(C(O3)COC4C(C(CO4)(CO)O)O)O)O)O)C(C)(C)OC5C(C(C(C(O5)COC6C(C(CO6)(CO)O)O)O)O)O","Ingredient_weight": "826.88","OB_score": "NA","CAS_id": "126054-82-8","SymMap_id": "NA","TCMID_id": "NA","TCMSP_id": "NA","TCM_ID_id": "6488","PubChem_id": "101831404","DrugBank_id": "NA"}

   

(2r,3r,4s,5s,6r)-2-{[(2s,4as,6r,8ar)-6-(2-{[(2s,3r,4s,5s,6r)-6-({[(2r,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy}methyl)-3,4,5-trihydroxyoxan-2-yl]oxy}propan-2-yl)-8a-methyl-4-methylidene-octahydronaphthalen-2-yl]oxy}-6-({[(2r,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy}methyl)oxane-3,4,5-triol

(2r,3r,4s,5s,6r)-2-{[(2s,4as,6r,8ar)-6-(2-{[(2s,3r,4s,5s,6r)-6-({[(2r,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy}methyl)-3,4,5-trihydroxyoxan-2-yl]oxy}propan-2-yl)-8a-methyl-4-methylidene-octahydronaphthalen-2-yl]oxy}-6-({[(2r,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy}methyl)oxane-3,4,5-triol

C37H62O20 (826.3834)


   

[(2r,3r,4r,4ar,6ar,6bs,8as,11r,12r,12as,14ar,14br)-2,12-dihydroxy-4,6a,6b,11,12,14b-hexamethyl-4-[(sulfooxy)methyl]-8a-({[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}carbonyl)-1,2,3,4a,5,6,7,8,9,10,11,12a,14,14a-tetradecahydropicen-3-yl]oxidanesulfonic acid

[(2r,3r,4r,4ar,6ar,6bs,8as,11r,12r,12as,14ar,14br)-2,12-dihydroxy-4,6a,6b,11,12,14b-hexamethyl-4-[(sulfooxy)methyl]-8a-({[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}carbonyl)-1,2,3,4a,5,6,7,8,9,10,11,12a,14,14a-tetradecahydropicen-3-yl]oxidanesulfonic acid

C36H58O17S2 (826.3115)


   

5-[(2s,3s)-3-({[2'-hydroxy-5,5'-bis(prop-2-en-1-yl)-[1,1'-biphenyl]-2-yl]oxy}methyl)-7-(prop-2-en-1-yl)-5-[4-(prop-2-en-1-yl)phenoxy]-2,3-dihydro-1,4-benzodioxin-2-yl]-3-[4-(prop-2-en-1-yl)phenoxy]benzene-1,2-diol

5-[(2s,3s)-3-({[2'-hydroxy-5,5'-bis(prop-2-en-1-yl)-[1,1'-biphenyl]-2-yl]oxy}methyl)-7-(prop-2-en-1-yl)-5-[4-(prop-2-en-1-yl)phenoxy]-2,3-dihydro-1,4-benzodioxin-2-yl]-3-[4-(prop-2-en-1-yl)phenoxy]benzene-1,2-diol

C54H50O8 (826.3506)


   

5-[3-({[2'-hydroxy-5,5'-bis(prop-2-en-1-yl)-[1,1'-biphenyl]-2-yl]oxy}methyl)-7-(prop-2-en-1-yl)-5-[4-(prop-2-en-1-yl)phenoxy]-2,3-dihydro-1,4-benzodioxin-2-yl]-3-[4-(prop-2-en-1-yl)phenoxy]benzene-1,2-diol

5-[3-({[2'-hydroxy-5,5'-bis(prop-2-en-1-yl)-[1,1'-biphenyl]-2-yl]oxy}methyl)-7-(prop-2-en-1-yl)-5-[4-(prop-2-en-1-yl)phenoxy]-2,3-dihydro-1,4-benzodioxin-2-yl]-3-[4-(prop-2-en-1-yl)phenoxy]benzene-1,2-diol

C54H50O8 (826.3506)


   

3-[(21s)-6-benzyl-5,8,17,20,23-pentahydroxy-15-(1h-indol-3-ylmethyl)-18-(2-methylpropyl)-2,14-dioxo-1,4,7,13,16,19,22-heptaazatricyclo[22.3.0.0⁹,¹³]heptacosa-4,7,16,19,22-pentaen-21-yl]propanoic acid

3-[(21s)-6-benzyl-5,8,17,20,23-pentahydroxy-15-(1h-indol-3-ylmethyl)-18-(2-methylpropyl)-2,14-dioxo-1,4,7,13,16,19,22-heptaazatricyclo[22.3.0.0⁹,¹³]heptacosa-4,7,16,19,22-pentaen-21-yl]propanoic acid

C43H54N8O9 (826.4014)


   

5-[(2r,3r)-3-({[2'-hydroxy-5,5'-bis(prop-2-en-1-yl)-[1,1'-biphenyl]-2-yl]oxy}methyl)-7-(prop-2-en-1-yl)-5-[4-(prop-2-en-1-yl)phenoxy]-2,3-dihydro-1,4-benzodioxin-2-yl]-3-[4-(prop-2-en-1-yl)phenoxy]benzene-1,2-diol

5-[(2r,3r)-3-({[2'-hydroxy-5,5'-bis(prop-2-en-1-yl)-[1,1'-biphenyl]-2-yl]oxy}methyl)-7-(prop-2-en-1-yl)-5-[4-(prop-2-en-1-yl)phenoxy]-2,3-dihydro-1,4-benzodioxin-2-yl]-3-[4-(prop-2-en-1-yl)phenoxy]benzene-1,2-diol

C54H50O8 (826.3506)


   

{2,12-dihydroxy-4,6a,6b,11,12,14b-hexamethyl-4-[(sulfooxy)methyl]-8a-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}carbonyl)-1,2,3,4a,5,6,7,8,9,10,11,12a,14,14a-tetradecahydropicen-3-yl}oxidanesulfonic acid

{2,12-dihydroxy-4,6a,6b,11,12,14b-hexamethyl-4-[(sulfooxy)methyl]-8a-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}carbonyl)-1,2,3,4a,5,6,7,8,9,10,11,12a,14,14a-tetradecahydropicen-3-yl}oxidanesulfonic acid

C36H58O17S2 (826.3115)


   

(11r,16s)-13-{2-[2,4-dihydroxy-5-(3-methylbut-2-en-1-yl)phenyl]-5,6-dihydroxy-7-(3-methylbut-2-en-1-yl)-1-benzofuran-3-carbonyl}-5,14-dihydroxy-4,15-bis(3-methylbut-2-en-1-yl)-8,17-dioxatetracyclo[8.7.0.0²,⁷.0¹¹,¹⁶]heptadeca-1(10),2,4,6,12,14-hexaen-9-one

(11r,16s)-13-{2-[2,4-dihydroxy-5-(3-methylbut-2-en-1-yl)phenyl]-5,6-dihydroxy-7-(3-methylbut-2-en-1-yl)-1-benzofuran-3-carbonyl}-5,14-dihydroxy-4,15-bis(3-methylbut-2-en-1-yl)-8,17-dioxatetracyclo[8.7.0.0²,⁷.0¹¹,¹⁶]heptadeca-1(10),2,4,6,12,14-hexaen-9-one

C50H50O11 (826.3353)


   

7-({5-[(4-{[3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy}-3,5-dihydroxyoxan-2-yl)oxy]-4-hydroxy-6-methyloxan-2-yl}oxy)-3a-hydroxy-9a,11a-dimethyl-1-(5-oxo-2h-furan-3-yl)-tetradecahydrocyclopenta[a]phenanthren-2-yl acetate

7-({5-[(4-{[3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy}-3,5-dihydroxyoxan-2-yl)oxy]-4-hydroxy-6-methyloxan-2-yl}oxy)-3a-hydroxy-9a,11a-dimethyl-1-(5-oxo-2h-furan-3-yl)-tetradecahydrocyclopenta[a]phenanthren-2-yl acetate

C41H62O17 (826.3987)


   

(1r,2r,3as,3br,5ar,7s,9as,9bs,11ar)-7-{[(2r,4s,5s,6r)-5-{[(2s,3r,4s,5r)-4-{[(2s,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy}-3,5-dihydroxyoxan-2-yl]oxy}-4-hydroxy-6-methyloxan-2-yl]oxy}-3a-hydroxy-9a,11a-dimethyl-1-(5-oxo-2h-furan-3-yl)-tetradecahydrocyclopenta[a]phenanthren-2-yl acetate

(1r,2r,3as,3br,5ar,7s,9as,9bs,11ar)-7-{[(2r,4s,5s,6r)-5-{[(2s,3r,4s,5r)-4-{[(2s,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy}-3,5-dihydroxyoxan-2-yl]oxy}-4-hydroxy-6-methyloxan-2-yl]oxy}-3a-hydroxy-9a,11a-dimethyl-1-(5-oxo-2h-furan-3-yl)-tetradecahydrocyclopenta[a]phenanthren-2-yl acetate

C41H62O17 (826.3987)


   

(1r,2r,3as,3bs,9br,11ar)-2,7-dihydroxy-3a,6,9b,11a-tetramethyl-8-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-({[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}-1-[(2r,3s,4e)-2,3,6-trihydroxy-6-methylhept-4-en-2-yl]-1h,2h,3h,3bh,4h,5h,11h-cyclopenta[a]phenanthren-10-one

(1r,2r,3as,3bs,9br,11ar)-2,7-dihydroxy-3a,6,9b,11a-tetramethyl-8-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-({[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}-1-[(2r,3s,4e)-2,3,6-trihydroxy-6-methylhept-4-en-2-yl]-1h,2h,3h,3bh,4h,5h,11h-cyclopenta[a]phenanthren-10-one

C41H62O17 (826.3987)


   

PIP(O-29:4)

PIP(O-29:4)

C38H68O15P2 (826.4033)


Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

   

PIP(O-9:0_20:4)

PIP(O-9:0_20:4)

C38H68O15P2 (826.4033)


Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

   

CL(28:4CHO)

CL(28:4(1CHO))

C37H64O16P2 (826.3669)


Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved